Related Experiment Video
Updated: Jul 25, 2025
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Characteristics of Phase IV Clinical Trials in Oncology: An Analysis Using the ClinicalTrials.gov Registry Data
Brandon Michael Henry1,2,3, Giuseppe Lippi4, Ameen Nasser5
1Cmed Research Inc., Morrisville, NC 27560, USA.
Abstract:
The present study analyzed the characteristics of phase IV clinical trials in oncology using data from the ClinicalTrials.gov registry. The included trials were conducted between January 2013 and December 2022 and were examined for key characteristics, including outcome measures, interventions, sample sizes, and study design, different cancer types, and geographic regions. The analysis included 368 phase IV oncology studies. An amount of 50% of these studies examined both safety and efficacy, while 43.5% only reported efficacy outcome measures, and 6.5% only described safety outcome measures. Only 16.9% of studies were powered to detect adverse events with a frequency of 1 in 100. Targeted therapies accounted for the majority of included studies (53.5%), with breast (32.91%) and hematological cancers (25.82%) being the most frequently investigated malignancies. Most phase IV oncology studies lacked sufficient power to detect rare adverse events due to their small sample sizes and instead focused on effectiveness. To ensure that there is no gap in drug safety data collection and detection of rare adverse events due to limited phase IV clinical trials, there is a significant need for additional education and participation by both health care providers and patients in spontaneous reporting processes.
Insights
Most phase IV oncology trials focus on effectiveness, not rare side effects, due to small sample sizes. Increased patient and provider participation in spontaneous reporting is crucial for comprehensive drug safety data.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacovigilance
Background:
- Phase IV clinical trials are essential for post-market drug surveillance in oncology.
- Understanding the characteristics of these trials is key to evaluating their effectiveness in detecting safety signals.
- Data from ClinicalTrials.gov provides a valuable resource for analyzing trends in oncology research.
Purpose of the Study:
- To analyze the characteristics of phase IV oncology clinical trials registered between 2013 and 2022.
- To assess the focus of these trials on efficacy versus safety outcome measures.
- To determine the power of these trials in detecting rare adverse events.
Main Methods:
- A systematic analysis of 368 phase IV oncology trials from ClinicalTrials.gov.
- Examination of trial characteristics including outcome measures, interventions, sample sizes, and study design.
- Evaluation of cancer types and geographic distribution of the included studies.
Main Results:
- 50% of trials assessed both safety and efficacy; 43.5% focused solely on efficacy.
- Only 16.9% of studies had adequate power to detect rare adverse events (frequency 1/100).
- Targeted therapies were most common (53.5%), with breast and hematological cancers being most studied.
Conclusions:
- Phase IV oncology trials often lack the statistical power to identify rare adverse events.
- The focus on efficacy over safety in many trials may create gaps in drug safety surveillance.
- Enhanced education and patient/provider engagement in spontaneous reporting systems are vital for robust pharmacovigilance.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:28Preclinical Development: Overview
02:56Treatment Resistant Cancers
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...